| Literature DB >> 27366328 |
Ping Wang1, Dao-Jiang Yu2, Gang Feng3, Zhen-Hai Long4, Chang-Jiang Liu4, Hui Li5, Tian-Lan Zhao2.
Abstract
Controversial findings are reported about the relationship between floppy eyelid syndrome (FES) and obstructive sleep apnea syndrome (OSAS). The main goal of this study was to evaluate whether FES is more prevalent in OSAS patients by performing a meta-analysis. A comprehensive literature search of Pubmed, Embase, and Cochrane databases was performed. Only studies related to the prevalence of FES in OSAS were included in the meta-analysis. We estimated a pooled odds ratio (OR) for the prevalence of FES in OSAS. In total, 6 studies with 767 participants met the inclusion criteria. Using a fixed-effects model, the pooled OR was 4.12. The test for the overall effect revealed that FES was statistically prevalent in OSAS patients when compared with that in non-OSAS subjects (Z = 4.98, p < 0.00001). In the subgroup analysis by OSAS severity, the incidence of FES in OSAS increased with severity of OSAS as indicated with increased OR values (OR = 2.56, 4.62, and 7.64 for mild, moderate, and severe OSAS). In conclusion, the results indicate that FES is more prevalent in OSAS patients. However, this result was based only on unadjusted estimates. Prospective cohort studies are needed to determine whether OSAS is an independent risk factor for FES.Entities:
Year: 2016 PMID: 27366328 PMCID: PMC4913017 DOI: 10.1155/2016/6980281
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Characteristics of the studies included in meta-analysis.
| Study | Mean age (years), non-OSAS/OSAS | Sex (F/M) | OSAS diagnosis | FES diagnosis | FES in OSAS | FES in non-OSAS | Statistically significant | Study quality score |
|---|---|---|---|---|---|---|---|---|
| Mojon et al., 1999 [ | Non-OSAS: 48.7 ± 13.7; | Non-OSAS: 6/22; | PSG. Hypopnea was defined as a 30% reduction in airflow accompanied by a 4% oxygen desaturation or a 50% reduction in airflow accompanied by a 3% oxygen desaturation or arousal. | Not presented | Mild: 2/9; | 1/28 | Yes | 3 |
|
| ||||||||
| Karger et al., 2006 [ | Non-OSAS: 43.2 ± 11.82; | Non-OSAS: 7/8; | PSG. Obstructive apnea was defined as cessation of airflow despite respiratory effort for at least 10 s. Hypopnea was defined as at least a 30% drop in airflow for at least 10 s despite respiratory effort and at least a 4% drop in oxyhemoglobin saturation | Subjectively easy eversion, papillary conjunctivitis, and lash ptosis | 1/44 | 0/15 | No | 4 |
|
| ||||||||
| Kadyan et al., 2010 [ | Non-OSAS: 55.3 ± 10.7; | Non-OSAS: 9/17; | Oximetry. ODI: events of 4% oxygen desaturation rate per hour. Non-OSAS: ODI < 5; mild: 5 ≤ ODI < 15; moderate: 15 ≤ ODI < 30; severe: ODI > 30 | Subjectively easy eversion, papillary conjunctivitis, and symptoms of ocular irritation | 28/89 | 1/26 | Yes | 5 |
|
| ||||||||
| Chambe et al., 2012 [ | Non-OSAS: 45.6 ± 1.9; | Non-OSAS: 19/19; | PSG. Hypopnea was defined as a 30% reduction in airflow accompanied by a 4% oxygen desaturation or a 50% reduction in airflow accompanied by a 3% oxygen desaturation or arousal. Non-OSAS: AHI ≤ 5; mild: 5 < AHI ≤ 15; moderate: 15 < AHI ≤ 30; severe: 30 < AHI | Eyelid hyperlaxity and papillary conjunctivitis | 23/89 | 6/38 | Yes | 5 |
|
| ||||||||
| Acar et al., 2013 [ | Non-OSAS: 46.7 ± 9; | Non-OSAS: 16/10; | PSG. Hypopnea was defined as a 30% reduction in airflow accompanied by a 4% oxygen desaturation or a 50% reduction in airflow accompanied by a 3% oxygen desaturation or arousal. Non-OSAS: AHI < 5; mild: 5 ≤ AHI < 15; moderate: 15 ≤ AHI ≤ 30; severe: 30 < AHI | Subjectively easy eversion and tarsal conjunctiva | Mild: 25/60; | 6/26 | Yes | 4 |
|
| ||||||||
| Muniesa Royo et al., 2013 [ | Non-OSAS: 48.6 ± 11.15; | Non-OSAS: 7/18; | PSG or cardiorespiratory sleep study. Obstructive apnea was defined as an absence of airflow for at least 10 s and hypopnea was defined as a clear (50%) airflow reduction for at least 10 s, with a drop in oxygen saturation of at least 4% or an arousal. Non-OSAS: AHI < 10; mild: 10 ≤ AHI < 20; moderate: 20 ≤ AHI ≤ 30; severe: AHI > 30 | Subjectively easy eversion and papillary conjunctivitis | Mild: 1/9; | 2/25 | No | 5 |
OSAS: obstructive sleep apnea/hypopnea syndrome; PSG: polysomnography; RDI: respiratory disturbance index; AHI: apneas or hypopneas index; ODI: oxygen desaturation index; BMI: body mass index.
Figure 1Flow diagram of the study identification, eligibility, and inclusion process.
Figure 2Forest plot of FES prevalence in OSAS. FES, floppy eyelid syndrome; OSAS, obstructive sleep apnea syndrome; CI, confidence interval.
Figure 3Forest plot of FES prevalence in OSAS subgroup according to severity of the disease. (a) FES prevalence in mild OSAS; (b) FES prevalence in moderate OSAS; (c) FES prevalence in severe OSAS. FES, floppy eyelid syndrome; OSAS, obstructive sleep apnea syndrome; CI, confidence interval.
Results of subgroup analysis. FE: fixed effect.
| Severity of OSAS | Number of studies | Weight of the studies (%) | Test of overall effect | Model | Heterogeneity | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mojon et al., 1999 [ | Acar et al., 2013 [ | Muniesa Royo et al., 2013 [ | OR (95% CI) |
|
|
|
|
| |||
| Mild | 3 | 6.1 | 78.7 | 15.2 | 2.56 | 2.06 | 0.04 | FE | 0.94 | 0.62 | 0 |
| Moderate | 3 | 9.6 | 56.1 | 34.3 | 4.62 | 3.56 | 0.0004 | FE | 2.52 | 0.28 | 21 |
| Severe | 3 | 10.4 | 47.6 | 42.0 | 7.64 | 5.00 | <0.0001 | FE | 2.31 | 0.32 | 13 |
Results of the sensitivity analysis.
| Excluded study | FES in OSAS | ||||
|---|---|---|---|---|---|
| Heterogeneity | Overall effect | ||||
|
|
|
|
|
| |
| Mojon et al., 1999 [ | 5.10 | 22% | 0.28 | 4.41 | <0.0001 |
| Karger et al., 2006 [ | 5.71 | 30% | 0.22 | 5.02 | <0.0001 |
| Kadyan et al., 2010 [ | 4.97 | 20% | 0.29 | 4.28 | <0.0001 |
| Chambe et al., 2012 [ | 3.41 | 0% | 0.49 | 4.92 | <0.00001 |
| Acar et al., 2013 [ | 4.92 | 19% | 0.30 | 3.59 | =0.0003 |
| Muniesa Royo et al., 2013 [ | 5.74 | 30% | 0.22 | 4.96 | <0.00001 |
Figure 4Funnel plot of the prevalence of FES in OSAS. FES, floppy eyelid syndrome; OSAS, obstructive sleep apnea syndrome.